Company intelligence / Profile preview

PetDx

San Diego, California, United States

Ownership: Private
Employees: ~17
Development stage: Other

Overview

PetDx developed and commercialized OncoK9, a first-in-class multi-cancer early detection (MCED) liquid biopsy blood test for dogs, supported by a large clinical validation program (CANDiD) involving ~1,600 dogs and showing high detection rates and low false positives across multiple canine cancer types; operations ceased in early 2024, but published studies and clinical data remain part of the veterinary oncology literature.[5][4][3]

Therapeutic areas: Oncology
Modalities: Diagnostic testNext-generation sequencingLiquid biopsy
Industry: Veterinary

Partnerships

Petco (distribution of OncoK9 in full-service veterinary hospitals)[5][4]IDEXX Laboratories (reference lab distribution partnership in US and Canada)[7]Antech (distribution partnership)[4]

Beyond the preview

Go deeper on PetDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PetDx.

Explore the full profile